ペプチド治療の市場規模、シェア、動向分析レポート：用途別、タイプ別、メーカータイプ別、投与経路別、合成技術別、地域別、セグメント予測、2025年～2030年

ペプチド治療市場の成長と動向

Grand View Research, Inc.の最新レポートによると、世界のペプチド治療市場規模は2030年までに2,602億5,000万米ドルに達する見込みです。

2025～2030年のCAGRは10.77%で成長する見込みです。がんやその他の生活習慣病の治療のために、副作用の少ない効率的で即効性のある治療への需要の高まりが、市場成長を促進すると予測されています。がんの罹患率が上昇していることから、他の治療手段や低コストの治療選択肢の模索と導入が求められており、市場の牽引役となることが予想されます。さらに、高齢者の増加は、がんや糖尿病などの対象疾患の罹患率を誘発することにより、消費者ベースを広げると予想され、ペプチド治療の需要を促進すると期待されています。

国際がん研究機関（GLOBOCAN 2020）の報告書によると、2020年に新たに診断されるがん患者は世界で1,929万2,789人となり、がんによる死亡者数は995万8,133人となります。さらに、がんの5年間の有病率は世界で50,550,287人になると予測されました。2040年には、世界の新規がん患者数は2,888万7,940人に達すると予測されています。その結果、世界中でがんの発生率が高くなることは、予測期間中、ペプチド治療の開発に重要な役割を果たすと考えられています。それに加えて、化学療法や放射線療法の悪影響に対する医療提供者や患者の意識の高まりが、ペプチドベースの薬剤のような代替治療の重視の高まりに影響を与える主要要因となっています。

ペプチド製造プロセスにおける技術的進歩が、予測期間中の市場を牽引しています。製造業者や供給業者は、少ない時間と資本投資で効率的な薬剤分子を製造するための新技術の採用に注力しています。精製や自動化プロセスの改善、廃棄物の発生が少ないことも、市場成長のさらなる要因となっています。例えば、Amgenは2022年3月、ノースカロライナ州ホリースプリングスに最新のバイオ製造施設を正式に開設すると発表しました。2025年に開設予定のこの施設は、がんや心臓病といった深刻な病気を治療するアムジェンの医薬品の成長に対応するのに役立つと考えられます。

COVID-19の大流行は、診断の遅れ、治療介入、がん治療のための費用対効果の高い治療の開発に焦点を当てた臨床検査の阻害など、がん治療のスペクトラムに拍車をかけると予想され、がん治療のためのペプチド治療も例外ではない、2020年『Nature Cancer』に掲載された研究紙製は述べています。急性呼吸窮迫症候群（ARDS）や重症急性呼吸器感染症によって引き起こされる他の呼吸器疾患の治療のための15の合成ペプチドなど、2020年5月現在、COVID-19の治療のための21のペプチド医薬品があります。しかし、現在、がんや代謝性疾患などにおけるペプチド治療の実用化は、薬剤不足や運用上の問題、COVID-19以外の治療を含む臨床検査の進捗の遅れによって妨げられています。

例えば、2022年5月、EVER Pharmaは、ボルテゾミブが症候性骨髄腫とマントル細胞リンパ腫の治療としてEU全域で承認を取得したと発表した1。2022年5月、欧州委員会は、急性と慢性移植片対宿主病に対するNovartisのJakaviポストステロイド療法を承認しました。Jakaviは、欧州でステロイド抵抗性の移植片対宿主病患者に対して広く使用できる最初のJAK1/2阻害剤となります。2021年9月、Nimble TherapeuticsとIncyteは、さらなる新規ペプチド治療を発見するための戦略的共同研究を開始しました。

ペプチド治療市場レポートハイライト

• タイプ別では、ジェネリック医薬品が市場第2位。ペプチド治療のジェネリック医薬品の台頭は製薬産業の新たな動向です。
• アウトソーシング製造セグメントは、複雑な手順が要求され、製造コストの削減に役立つアウトソーシングへの嗜好の変化により、予測期間中に最も速いCAGRで成長すると予測されます。
• 合成技術別では、組換えDNA技術セグメントは2024年に79.26%の最大の収益シェアを占めました。
• 北米のペプチド治療市場は、がん、代謝性疾患、希少疾患の有病率の上昇に牽引され、2024年の世界シェアは60.21%で主導的地位を維持しています。

目次

第1章 調査手法と範囲

第2章 エグゼクティブサマリー

第3章 ペプチド治療市場の変数、動向、範囲

• 親市場の展望
• 補助市場の展望
• 市場力学
  • 市場促進要因分析
  • 市場抑制要因分析
• ペプチド治療分析ツール
  • ポーターの分析
  • PESTEL分析
• パイプライン分析
  • フェーズ1
  • フェーズ2
  • フェーズ3
• フェーズ3パイプライン医薬品予測
• 使用事例分析

第4章 ペプチド治療市場：用途別、推定・動向分析

• ペプチド治療市場：用途セグメントダッシュボード
• ペプチド治療市場：用途変動分析、2024年と2030年
• 代謝障害
• がん
• 神経疾患
• 胃腸障害
• 心血管疾患
• 痛み
• 感染症
• 腎疾患
• 皮膚疾患
• 呼吸器疾患
• その他

第5章 ペプチド治療市場：タイプ別、推定・動向分析

• ペプチド治療市場：タイプセグメントダッシュボード
• ペプチド治療市場：タイプ変動分析、2024年と2030年
• イノベーティブ
• ジェネリック

第6章 ペプチド治療市場：メーカータイプ別、推定・動向分析

• ペプチド治療市場：メーカータイプセグメントダッシュボード
• ペプチド治療市場：メーカータイプ変動分析、2024年と2030年
• 社内
• アウトソーシング

第7章 ペプチド治療市場：合成技術別、推定・動向分析

• ペプチド治療市場：合成技術セグメントダッシュボード
• ペプチド治療市場：合成技術変動分析、2024年と2030年
• 組み換えDNA技術
• 固相ペプチド合成（SPPS）
• ハイブリッド
• 液相ペプチド合成（LPPS）
• その他

第8章 ペプチド治療市場：投与経路別、推定・動向分析

• ペプチド治療市場：投与経路セグメントダッシュボード
• ペプチド治療市場：投与経路変動分析、2024年と2030年
• 非経口投与
• 経口投与
• 粘膜
• 肺
• その他

第9章 ペプチド治療市場：地域別、推定・動向分析

• ペプチド治療市場シェア、地域別、2024年と2030年、100万米ドル
• 北米
  • 米国
  • カナダ
  • メキシコ
• 欧州
  • 英国
  • ドイツ
  • フランス
  • イタリア
  • スペイン
  • デンマーク
  • スウェーデン
  • ノルウェー
• アジア太平洋
  • 日本
  • 中国
  • インド
  • オーストラリア
  • 韓国
  • タイ
• ラテンアメリカ
  • ブラジル
  • アルゼンチン
• 中東・アフリカ
  • 南アフリカ
  • サウジアラビア
  • アラブ首長国連邦
  • クウェート

第10章 競合情勢

• 主要市場参入企業による最近の動向と影響分析
• 企業分類
• 参加者概要
• Product Bench Marking
• 企業市場シェア分析、2024年
• 企業プロファイル
  • Eli Lilly and Company
  • Pfizer Inc.
  • Amgen Inc.
  • Takeda Pharmaceutical Company Limited
  • AstraZeneca
  • Teva Pharmaceutical Industries Ltd.
  • Sanofi
  • F. Hoffmann-La Roche Ltd
  • Novartis AG
  • Novo Nordisk A/S
  • GSK plc
  • Ironwood Pharmaceuticals, Inc.
  • Radius Health, Inc.（Gurnet Point Capital and Patient Square Capitalの子会社）
  • Ipsen Pharma

第11章 結論/主要ポイント/KoL洞察

List of Tables

• Table 1 List of secondary sources
• Table 2 List of abbreviations
• Table 3 North America peptide therapeutics market estimates and forecasts, by country, 2018 - 2030 (USD Million)
• Table 4 North America peptide therapeutics market estimates and forecasts, by application, 2018 - 2030 (USD Million)
• Table 5 North America peptide therapeutics market estimates and forecasts, by type, 2018 - 2030 (USD Million)
• Table 6 North America peptide therapeutics market estimates and forecasts, by type of manufacturer, 2018 - 2030 (USD Million)
• Table 7 North America peptide therapeutics market estimates and forecasts, by route of administration, 2018 - 2030 (USD Million)
• Table 8 North America peptide therapeutics market estimates and forecasts, by synthesis technology, 2018 - 2030 (USD Million)
• Table 9 U.S. peptide therapeutics market estimates and forecasts, by application, 2018 - 2030 (USD Million)
• Table 10 U.S. peptide therapeutics market estimates and forecasts, by type, 2018 - 2030 (USD Million)
• Table 11 U.S. peptide therapeutics market estimates and forecasts, by type of manufacturers, 2018 - 2030 (USD Million)
• Table 12 U.S. peptide therapeutics market estimates and forecasts, by route of administration, 2018 - 2030 (USD Million)
• Table 13 U.S. peptide therapeutics market estimates and forecasts, by synthesis technology, 2018 - 2030 (USD Million)
• Table 14 Canada peptide therapeutics market estimates and forecasts, by application, 2018 - 2030 (USD Million)
• Table 15 Canada peptide therapeutics market estimates and forecasts, by type, 2018 - 2030 (USD Million)
• Table 16 Canada peptide therapeutics market estimates and forecasts, by type of manufacturers, 2018 - 2030 (USD Million)
• Table 17 Canada peptide therapeutics market estimates and forecasts, by route of administration, 2018 - 2030 (USD Million)
• Table 18 Canada peptide therapeutics market estimates and forecasts, by synthesis technology, 2018 - 2030 (USD Million)
• Table 19 Mexico peptide therapeutics market estimates and forecasts, by application, 2018 - 2030 (USD Million)
• Table 20 Mexico peptide therapeutics market estimates and forecasts, by type, 2018 - 2030 (USD Million)
• Table 21 Mexico peptide therapeutics market estimates and forecasts, by type of manufacturers, 2018 - 2030 (USD Million)
• Table 22 Mexico peptide therapeutics market estimates and forecasts, by route of administration, 2018 - 2030 (USD Million)
• Table 23 Mexico peptide therapeutics market estimates and forecasts, by synthesis technology, 2018 - 2030 (USD Million)
• Table 24 Europe peptide therapeutics market estimates and forecasts, by country, 2018 - 2030 (USD Million)
• Table 25 Europe peptide therapeutics market estimates and forecasts, by application, 2018 - 2030 (USD Million)
• Table 26 Europe peptide therapeutics market estimates and forecasts, by type, 2018 - 2030 (USD Million)
• Table 27 Europe peptide therapeutics market estimates and forecasts, by type of manufacturers, 2018 - 2030 (USD Million)
• Table 28 Europe peptide therapeutics market estimates and forecasts, by route of administration, 2018 - 2030 (USD Million)
• Table 29 Europe peptide therapeutics market estimates and forecasts, by synthesis technology, 2018 - 2030 (USD Million)
• Table 30 UK peptide therapeutics market estimates and forecasts, by application, 2018 - 2030 (USD Million)
• Table 31 UK peptide therapeutics market estimates and forecasts, by type, 2018 - 2030 (USD Million)
• Table 32 UK peptide therapeutics market estimates and forecasts, by type of manufacturers, 2018 - 2030 (USD Million)
• Table 33 UK peptide therapeutics market estimates and forecasts, by route of administration, 2018 - 2030 (USD Million)
• Table 34 UK peptide therapeutics market estimates and forecasts, by synthesis technology, 2018 - 2030 (USD Million)
• Table 35 Germany peptide therapeutics market estimates and forecasts, by application, 2018 - 2030 (USD Million)
• Table 36 Germany peptide therapeutics market estimates and forecasts, by type, 2018 - 2030 (USD Million)
• Table 37 Germany peptide therapeutics market estimates and forecasts, by type of manufacturers, 2018 - 2030 (USD Million)
• Table 38 Germany peptide therapeutics market estimates and forecasts, by route of administration, 2018 - 2030 (USD Million)
• Table 39 Germany peptide therapeutics market estimates and forecasts, by synthesis technology, 2018 - 2030 (USD Million)
• Table 40 France peptide therapeutics market estimates and forecasts, by application, 2018 - 2030 (USD Million)
• Table 41 France peptide therapeutics market estimates and forecasts, by type, 2018 - 2030 (USD Million)
• Table 42 France peptide therapeutics market estimates and forecasts, by type of manufacturers, 2018 - 2030 (USD Million)
• Table 43 France peptide therapeutics market estimates and forecasts, by route of administration, 2018 - 2030 (USD Million)
• Table 44 France peptide therapeutics market estimates and forecasts, by synthesis technology, 2018 - 2030 (USD Million)
• Table 45 Spain peptide therapeutics market estimates and forecasts, by application, 2018 - 2030 (USD Million)
• Table 46 Spain peptide therapeutics market estimates and forecasts, by type, 2018 - 2030 (USD Million)
• Table 47 Spain peptide therapeutics market estimates and forecasts, by type of manufacturers, 2018 - 2030 (USD Million)
• Table 48 Spain peptide therapeutics market estimates and forecasts, by route of administration, 2018 - 2030 (USD Million)
• Table 49 Spain peptide therapeutics market estimates and forecasts, by synthesis technology, 2018 - 2030 (USD Million)
• Table 50 Italy peptide therapeutics market estimates and forecasts, by application, 2018 - 2030 (USD Million)
• Table 51 Italy peptide therapeutics market estimates and forecasts, by type, 2018 - 2030 (USD Million)
• Table 52 Italy peptide therapeutics market estimates and forecasts, by type of manufacturers, 2018 - 2030 (USD Million)
• Table 53 Italy peptide therapeutics market estimates and forecasts, by route of administration, 2018 - 2030 (USD Million)
• Table 54 Italy peptide therapeutics market estimates and forecasts, by synthesis technology, 2018 - 2030 (USD Million)
• Table 55 Denmark peptide therapeutics market estimates and forecasts, by application, 2018 - 2030 (USD Million)
• Table 56 Denmark peptide therapeutics market estimates and forecasts, by type, 2018 - 2030 (USD Million)
• Table 57 Denmark peptide therapeutics market estimates and forecasts, by type of manufacturers, 2018 - 2030 (USD Million)
• Table 58 Denmark peptide therapeutics market estimates and forecasts, by route of administration, 2018 - 2030 (USD Million)
• Table 59 Denmark peptide therapeutics market estimates and forecasts, by synthesis technology, 2018 - 2030 (USD Million)
• Table 60 Sweden peptide therapeutics market estimates and forecasts, by application, 2018 - 2030 (USD Million)
• Table 61 Sweden peptide therapeutics market estimates and forecasts, by type, 2018 - 2030 (USD Million)
• Table 62 Sweden peptide therapeutics market estimates and forecasts, by type of manufacturers, 2018 - 2030 (USD Million)
• Table 63 Sweden peptide therapeutics market estimates and forecasts, by route of administration, 2018 - 2030 (USD Million)
• Table 64 Sweden peptide therapeutics market estimates and forecasts, by synthesis technology, 2018 - 2030 (USD Million)
• Table 65 Norway peptide therapeutics market estimates and forecasts, by application, 2018 - 2030 (USD Million)
• Table 66 Norway peptide therapeutics market estimates and forecasts, by type, 2018 - 2030 (USD Million)
• Table 67 Norway peptide therapeutics market estimates and forecasts, by type of manufacturers, 2018 - 2030 (USD Million)
• Table 68 Norway peptide therapeutics market estimates and forecasts, by route of administration, 2018 - 2030 (USD Million)
• Table 69 Norway peptide therapeutics market estimates and forecasts, by synthesis technology, 2018 - 2030 (USD Million)
• Table 70 Asia Pacific peptide therapeutics market estimates and forecasts, by country, 2018 - 2030 (USD Million)
• Table 71 Asia Pacific peptide therapeutics market estimates and forecasts, by application, 2018 - 2030 (USD Million)
• Table 72 Asia Pacific peptide therapeutics market estimates and forecasts, by type, 2018 - 2030 (USD Million)
• Table 73 Asia Pacific peptide therapeutics market estimates and forecasts, by type of manufacturers, 2018 - 2030 (USD Million)
• Table 74 Asia Pacific peptide therapeutics market estimates and forecasts, by route of administration, 2018 - 2030 (USD Million)
• Table 75 Asia Pacific peptide therapeutics market estimates and forecasts, by synthesis technology, 2018 - 2030 (USD Million)
• Table 76 Japan peptide therapeutics market estimates and forecasts, by application, 2018 - 2030 (USD Million)
• Table 77 Japan peptide therapeutics market estimates and forecasts, by type, 2018 - 2030 (USD Million)
• Table 78 Japan peptide therapeutics market estimates and forecasts, by type of manufacturers, 2018 - 2030 (USD Million)
• Table 79 Japan peptide therapeutics market estimates and forecasts, by route of administration, 2018 - 2030 (USD Million)
• Table 80 Japan peptide therapeutics market estimates and forecasts, by synthesis technology, 2018 - 2030 (USD Million)
• Table 81 China peptide therapeutics market estimates and forecasts, by application, 2018 - 2030 (USD Million)
• Table 82 China peptide therapeutics market estimates and forecasts, by type, 2018 - 2030 (USD Million)
• Table 83 China peptide therapeutics market estimates and forecasts, by type of manufacturers, 2018 - 2030 (USD Million)
• Table 84 China peptide therapeutics market estimates and forecasts, by route of administration, 2018 - 2030 (USD Million)
• Table 85 China peptide therapeutics market estimates and forecasts, by synthesis technology, 2018 - 2030 (USD Million)
• Table 86 India peptide therapeutics market estimates and forecasts, by application, 2018 - 2030 (USD Million)
• Table 87 India peptide therapeutics market estimates and forecasts, by type, 2018 - 2030 (USD Million)
• Table 88 India peptide therapeutics market estimates and forecasts, by type of manufacturers, 2018 - 2030 (USD Million)
• Table 89 India peptide therapeutics market estimates and forecasts, by route of administration, 2018 - 2030 (USD Million)
• Table 90 India peptide therapeutics market estimates and forecasts, by synthesis technology, 2018 - 2030 (USD Million)
• Table 91 South Korea peptide therapeutics market estimates and forecasts, by application, 2018 - 2030 (USD Million)
• Table 92 South Korea peptide therapeutics market estimates and forecasts, by type, 2018 - 2030 (USD Million)
• Table 93 South Korea peptide therapeutics market estimates and forecasts, by type of manufacturers, 2018 - 2030 (USD Million)
• Table 94 South Korea peptide therapeutics market estimates and forecasts, by route of administration, 2018 - 2030 (USD Million)
• Table 95 South Korea peptide therapeutics market estimates and forecasts, by synthesis technology, 2018 - 2030 (USD Million)
• Table 96 Australia peptide therapeutics market estimates and forecasts, by application, 2018 - 2030 (USD Million)
• Table 97 Australia peptide therapeutics market estimates and forecasts, by type, 2018 - 2030 (USD Million)
• Table 98 Australia peptide therapeutics market estimates and forecasts, by type of manufacturers, 2018 - 2030 (USD Million)
• Table 99 Australia peptide therapeutics market estimates and forecasts, by route of administration, 2018 - 2030 (USD Million)
• Table 100 Australia peptide therapeutics market estimates and forecasts, by synthesis technology, 2018 - 2030 (USD Million)
• Table 101 Thailand peptide therapeutics market estimates and forecasts, by application, 2018 - 2030 (USD Million)
• Table 102 Thailand peptide therapeutics market estimates and forecasts, by type, 2018 - 2030 (USD Million)
• Table 103 Thailand peptide therapeutics market estimates and forecasts, by type of manufacturers, 2018 - 2030 (USD Million)
• Table 104 Thailand peptide therapeutics market estimates and forecasts, by route of administration, 2018 - 2030 (USD Million)
• Table 105 Thailand peptide therapeutics market estimates and forecasts, by synthesis technology, 2018 - 2030 (USD Million)
• Table 106 Latin America peptide therapeutics market estimates and forecasts, by country, 2018 - 2030 (USD Million)
• Table 107 Latin America peptide therapeutics market estimates and forecasts, by application, 2018 - 2030 (USD Million)
• Table 108 Latin America peptide therapeutics market estimates and forecasts, by type, 2018 - 2030 (USD Million)
• Table 109 Latin America peptide therapeutics market estimates and forecasts, by type of manufacturers, 2018 - 2030 (USD Million)
• Table 110 Latin America peptide therapeutics market estimates and forecasts, by route of administration, 2018 - 2030 (USD Million)
• Table 111 Latin America peptide therapeutics market estimates and forecasts, by synthesis technology, 2018 - 2030 (USD Million)
• Table 112 Brazil peptide therapeutics market estimates and forecasts, by route of administration, 2018 - 2030 (USD Million)
• Table 113 Brazil peptide therapeutics market estimates and forecasts, by synthesis technology, 2018 - 2030 (USD Million)
• Table 114 Argentina peptide therapeutics market estimates and forecasts, by application, 2018 - 2030 (USD Million)
• Table 115 Argentina peptide therapeutics market estimates and forecasts, by type, 2018 - 2030 (USD Million)
• Table 116 Argentina peptide therapeutics market estimates and forecasts, by type of manufacturers, 2018 - 2030 (USD Million)
• Table 117 Argentina peptide therapeutics market estimates and forecasts, by route of administration, 2018 - 2030 (USD Million)
• Table 118 Argentina peptide therapeutics market estimates and forecasts, by synthesis technology, 2018 - 2030 (USD Million)
• Table 119 MEA peptide therapeutics market estimates and forecasts, by country, 2018 - 2030 (USD Million)
• Table 120 MEA peptide therapeutics market estimates and forecasts, by application, 2018 - 2030 (USD Million)
• Table 121 MEA peptide therapeutics market estimates and forecasts, by type, 2018 - 2030 (USD Million)
• Table 122 MEA peptide therapeutics market estimates and forecasts, by type of manufacturers, 2018 - 2030 (USD Million)
• Table 123 MEA peptide therapeutics market estimates and forecasts, by route of administration, 2018 - 2030 (USD Million)
• Table 124 MEA peptide therapeutics market estimates and forecasts, by synthesis technology, 2018 - 2030 (USD Million)
• Table 125 South Africa peptide therapeutics market estimates and forecasts, by application, 2018 - 2030 (USD Million)
• Table 126 South Africa peptide therapeutics market estimates and forecasts, by type, 2018 - 2030 (USD Million)
• Table 127 South Africa peptide therapeutics market estimates and forecasts, by type of manufacturers, 2018 - 2030 (USD Million)
• Table 128 South Africa peptide therapeutics market estimates and forecasts, by route of administration, 2018 - 2030 (USD Million)
• Table 129 South Africa peptide therapeutics market estimates and forecasts, by synthesis technology, 2018 - 2030 (USD Million)
• Table 130 UAE peptide therapeutics market estimates and forecasts, by application, 2018 - 2030 (USD Million)
• Table 131 UAE peptide therapeutics market estimates and forecasts, by type, 2018 - 2030 (USD Million)
• Table 132 UAE peptide therapeutics market estimates and forecasts, by type of manufacturers, 2018 - 2030 (USD Million)
• Table 133 UAE peptide therapeutics market estimates and forecasts, by route of administration, 2018 - 2030 (USD Million)
• Table 134 UAE peptide therapeutics market estimates and forecasts, by synthesis technology, 2018 - 2030 (USD Million)
• Table 135 Saudi Arabia peptide therapeutics market estimates and forecasts, by application, 2018 - 2030 (USD Million)
• Table 136 Saudi Arabia peptide therapeutics market estimates and forecasts, by type, 2018 - 2030 (USD Million)
• Table 137 Saudi Arabia peptide therapeutics market estimates and forecasts, by type of manufacturers, 2018 - 2030 (USD Million)
• Table 138 Saudi Arabia peptide therapeutics market estimates and forecasts, by route of administration, 2018 - 2030 (USD Million)
• Table 139 Saudi Arabia peptide therapeutics market estimates and forecasts, by synthesis technology, 2018 - 2030 (USD Million)
• Table 140 Kuwait peptide therapeutics market estimates and forecasts, by application, 2018 - 2030 (USD Million)
• Table 141 Kuwait peptide therapeutics market estimates and forecasts, by type, 2018 - 2030 (USD Million)
• Table 142 Kuwait peptide therapeutics market estimates and forecasts, by type of manufacturers, 2018 - 2030 (USD Million)
• Table 143 Kuwait peptide therapeutics market estimates and forecasts, by route of administration, 2018 - 2030 (USD Million)
• Table 144 Kuwait peptide therapeutics market estimates and forecasts, by synthesis technology, 2018 - 2030 (USD Million)
• Table 145 Kuwait peptide therapeutics market estimates and forecasts, by type of manufacturers, 2018 - 2030 (USD Million)
• Table 146 Kuwait peptide therapeutics market estimates and forecasts, by route of administration, 2018 - 2030 (USD Million)
• Table 147 Kuwait peptide therapeutics market estimates and forecasts, by synthesis technology, 2018 - 2030 (USD Million)

List of Figures

• Fig. 1 Peptide therapeutics market segmentation
• Fig. 2 Market research process
• Fig. 3 Data triangulation techniques
• Fig. 4 Primary research pattern
• Fig. 5 Value chain-based sizing & forecasting
• Fig. 6 QFD modelling for market share assessment
• Fig. 7 Market formulation & validation
• Fig. 8 Market snapshot
• Fig. 9 Application segment snapshot
• Fig. 10 Type and type of manufacturers segment snapshot
• Fig. 11 Route of administration and synthesis technology segment snapshot
• Fig. 12 Competitive landscape snapshot
• Fig. 13 Pharmaceutical market, (USD Billion)
• Fig. 14 Market dynamics
• Fig. 15 The most common cancers globally are listed in the table below
• Fig. 16 Global number of new cases caused by top 11 cancer types in 2023 (in thousands)
• Fig. 17 The figure below shows the phase of therapeutic peptides in clinical trials
• Fig. 18 Porter's five forces analysis
• Fig. 19 PESTLE analysis
• Fig. 20 Peptide therapeutics market: Application outlook and key takeaways
• Fig. 21 Peptide therapeutics market: Application movement analysis
• Fig. 22 Cancer market estimates and forecast, 2018 - 2030 (USD Million)
• Fig. 23 Metabolic disorders market estimates and forecast, 2018 - 2030 (USD Million)
• Fig. 24 Cardiovascular disorders market estimates and forecast, 2018 - 2030 (USD Million)
• Fig. 25 Respiratory disorders market estimates and forecasts, 2018 - 2030 (USD Million)
• Fig. 26 Gastrointestinal disorders market estimates and forecast, 2018 - 2030 (USD Million)
• Fig. 27 Infectious diseases market estimates and forecast, 2018 - 2030 (USD Million)
• Fig. 28 Pain market estimates and forecast, 2018 - 2030 (USD Million)
• Fig. 29 Dermatological disorders market estimates and forecast, 2018 - 2030 (USD Million)
• Fig. 30 Neurological disorders market estimates and forecast, 2018 - 2030 (USD Million)
• Fig. 31 Renal disorders market estimates and forecast, 2018 - 2030 (USD Million)
• Fig. 32 Others market estimates and forecast, 2018 - 2030 (USD Million)
• Fig. 33 Peptide therapeutics market: Type outlook and key takeaways
• Fig. 34 Peptide therapeutics market: Type movement analysis
• Fig. 35 Generic market estimates and forecast, 2018 - 2030 (USD Million)
• Fig. 36 Innovative market estimates and forecast, 2018 - 2030 (USD Million)
• Fig. 37 Peptide therapeutics market: Type of manufacturers outlook and key takeaways
• Fig. 38 Peptide therapeutics market: Type of manufacturers movement analysis
• Fig. 39 In-house market estimates and forecast, 2018 - 2030 (USD Million)
• Fig. 40 Outsourced market estimates and forecast, 2018 - 2030 (USD Million)
• Fig. 41 Peptide therapeutics market: Route of administration outlook and key takeaways
• Fig. 42 Peptide therapeutics market: Route of administration movement analysis
• Fig. 43 Parenteral route market estimates and forecast, 2018 - 2030 (USD Million)
• Fig. 44 Oral route market estimates and forecast, 2018 - 2030 (USD Million)
• Fig. 45 Pulmonary market estimates and forecast, 2018 - 2030 (USD Million)
• Fig. 46 Mucosal market estimates and forecast, 2018 - 2030 (USD Million)
• Fig. 47 Others market estimates and forecast, 2018 - 2030 (USD Million)
• Fig. 48 Peptide therapeutics market: Synthesis technology outlook and key takeaways
• Fig. 49 Peptide therapeutics market: Synthesis technology movement analysis
• Fig. 50 Solid Phase Peptide Synthesis (SPPS) market estimates and Forecast, 2018 - 2030 (USD Million)
• Fig. 51 Recombinant DNA technology market estimates and forecast, 2018 - 2030 (USD Million)
• Fig. 52 Hybrid technology market estimates and forecast, 2018 - 2030 (USD Million)
• Fig. 53 Liquid-Phase Peptide Synthesis (LPPS) technology market estimates and forecast, 2018 - 2030 (USD Million)
• Fig. 54 Others market estimates and forecast, 2018 - 2030 (USD Million)
• Fig. 55 Peptide therapeutics market revenue, by region, 2024 & 2030, (USD Million)
• Fig. 56 Regional marketplace: Key takeaways
• Fig. 57 Regional marketplace: Key takeaways
• Fig. 58 North America peptide therapeutics market estimates and forecasts, 2018 - 2030 (USD Million)
• Fig. 59 Key country dynamics
• Fig. 60 Target disease prevalence
• Fig. 61 U.S. peptide therapeutics market estimates and forecasts, 2018 - 2030 (USD Million)
• Fig. 62 Key country dynamics
• Fig. 63 Target disease prevalence
• Fig. 64 Canada peptide therapeutics market estimates and forecasts, 2018 - 2030 (USD Million)
• Fig. 65 Mexico peptide therapeutics market estimates and forecasts, 2018 - 2030 (USD Million)
• Fig. 66 Key country dynamics
• Fig. 67 Target disease prevalence
• Fig. 68 Europe peptide therapeutics market estimates and forecasts, 2018 - 2030 (USD Million)
• Fig. 69 Key country dynamics
• Fig. 70 Target disease prevalence
• Fig. 71 UK peptide therapeutics market estimates and forecasts, 2018 - 2030 (USD Million)
• Fig. 72 Key country dynamics
• Fig. 73 Target disease prevalence
• Fig. 74 Germany peptide therapeutics market estimates and forecasts, 2018 - 2030 (USD Million)
• Fig. 75 Key country dynamics
• Fig. 76 Target disease prevalence
• Fig. 77 France peptide therapeutics market estimates and forecasts, 2018 - 2030 (USD Million)
• Fig. 78 Key country dynamics
• Fig. 79 Target disease prevalence
• Fig. 80 Spain peptide therapeutics market estimates and forecasts, 2018 - 2030 (USD Million)
• Fig. 81 Key country dynamics
• Fig. 82 Target disease prevalence
• Fig. 83 Italy peptide therapeutics market estimates and forecasts, 2018 - 2030 (USD Million)
• Fig. 84 Key country dynamics
• Fig. 85 Target disease prevalence
• Fig. 86 Denmark peptide therapeutics market estimates and forecasts, 2018 - 2030 (USD Million)
• Fig. 87 Key country dynamics
• Fig. 88 Target disease prevalence
• Fig. 89 Sweden peptide therapeutics market estimates and forecasts, 2018 - 2030 (USD Million)
• Fig. 90 Key country dynamics
• Fig. 91 Target disease prevalence
• Fig. 92 Norway peptide therapeutics market estimates and forecasts, 2018 - 2030 (USD Million)
• Fig. 93 Rest of Europe peptide therapeutics market estimates and forecasts, 2018 - 2030 (USD Million)
• Fig. 94 Asia Pacific peptide therapeutics market estimates and forecasts, 2018 - 2030 (USD Million)
• Fig. 95 Key country dynamics
• Fig. 96 Target disease prevalence
• Fig. 97 Japan peptide therapeutics market estimates and forecasts, 2018 - 2030 (USD Million)
• Fig. 98 Key country dynamics
• Fig. 99 Target disease prevalence
• Fig. 100 China peptide therapeutics market estimates and forecasts, 2018 - 2030 (USD Million)
• Fig. 101 Key country dynamics
• Fig. 102 Target disease prevalence
• Fig. 103 India peptide therapeutics market estimates and forecasts, 2018 - 2030 (USD Million)
• Fig. 104 Key country dynamics
• Fig. 105 Target disease prevalence
• Fig. 106 Australia peptide therapeutics market estimates and forecasts, 2018 - 2030 (USD Million)
• Fig. 107 Key country dynamics
• Fig. 108 Thailand peptide therapeutics market estimates and forecasts, 2018 - 2030 (USD Million)
• Fig. 109 Key country dynamics
• Fig. 110 South Korea peptide therapeutics market estimates and forecasts, 2018 - 2030 (USD Million)
• Fig. 111 Rest of Asia Pacific peptide therapeutics market estimates and forecasts, 2018 - 2030 (USD Million)
• Fig. 112 Latin America peptide therapeutics market estimates and forecasts, 2018 - 2030 (USD Million)
• Fig. 113 Key country dynamics
• Fig. 114 Target disease prevalence
• Fig. 115 Brazil peptide therapeutics market estimates and forecasts, 2018 - 2030 (USD Million)
• Fig. 116 Key country dynamics
• Fig. 117 Target disease prevalence
• Fig. 118 Argentina peptide therapeutics market estimates and forecasts, 2018 - 2030 (USD Million)
• Fig. 119 Rest of Latin America peptide therapeutics market estimates and forecasts, 2018 - 2030 (USD Million)
• Fig. 120 MEA peptide therapeutics market estimates and forecasts, 2018 - 2030 (USD Million)
• Fig. 121 Key country dynamics
• Fig. 122 Target disease prevalence
• Fig. 123 South Africa peptide therapeutics market estimates and forecasts, 2018 - 2030 (USD Million)
• Fig. 124 Key country dynamics
• Fig. 125 Target disease prevalence
• Fig. 126 Saudi Arabia peptide therapeutics market estimates and forecasts, 2018 - 2030 (USD Million)
• Fig. 127 Key country dynamics
• Fig. 128 Target disease prevalence
• Fig. 129 UAE peptide therapeutics market estimates and forecasts, 2018 - 2030 (USD Million)
• Fig. 130 Key country dynamics
• Fig. 131 Target disease prevalence
• Fig. 132 Kuwait peptide therapeutics market estimates and forecasts, 2018 - 2030 (USD Million)
• Fig. 133 Rest of MEA peptide therapeutics market estimates and forecasts, 2018 - 2030 (USD Million)

Peptide Therapeutics Market Growth & Trends:

The global peptide therapeutics market size is expected to reach USD 260.25 billion by 2030, according to a new report by Grand View Research, Inc. It is expected to grow at a CAGR of 10.77% from 2025 to 2030. Increasing demand for efficient and rapid-acting therapeutics for the treatment of cancer and other lifestyle-associated disorders, which result in lesser adverse effects, is anticipated to propel market growth. The rising incidence of cancer calls for exploring and introducing other means of therapies and low-cost treatment alternatives is expected to drive the market. Moreover, the growing geriatric population is expected to widen the consumer base by triggering the incidence rate of target diseases such as cancer and diabetes, which is expected to drive the demand for peptide therapeutics.

As per the International Agency for Research on Cancer (GLOBOCAN 2020) report, there will be 19,292,789 new cancer cases diagnosed globally in 2020, with 9,958,133 cancer deaths. Furthermore, the five-year prevalence of cancer was projected to be 50,550,287 worldwide. The global number of new cases of cancer is projected to reach 28,887,940 by 2040. As a result, the higher incidence of cancers around the world is set to perform an important role in the development of peptide therapeutics over the forecast period. Besides that, increasing awareness among health care providers and patients about the negative effects of chemotherapy and/or radiation therapy is a primary factor influencing the increased emphasis on alternative therapeutics like peptide-based drugs.

Technological advancements in the peptide manufacturing process are driving the market during the forecast period. Manufacturers and suppliers are focusing on the adoption of novel technologies to manufacture efficient drug molecules with low time and capital investment. Improvement in purification and automation process and less generation of waste are additional factors contributing to the market growth. For instance, in March 2022, Amgen announced the official opening of its latest bio-manufacturing facility in Holly Springs, North Carolina. The facility, which is set to open in 2025, will help cope with the growth of Amgen's medicines, which treat serious diseases like cancer and heart disease.

The COVID-19 pandemic is anticipated to spur the spectrum of cancer care, which includes delayed diagnoses, therapeutic interventions, and the impeding of clinical trials focused on developing cost-effective therapeutics for cancer treatment, with peptide therapeutics for cancer treatment being no exception, as per a research article published in Nature Cancer, 2020. There have been 21 peptide drugs in therapies for the treatment of COVID-19 as of May 2020, such as 15 synthetic peptides for the therapies of acute respiratory distress syndrome (ARDS) as well as other respiratory illnesses induced by severe acute respiratory infection. However, current implementations of peptide therapeutics in oncological and metabolic disorders and other fields have been hampered by drug shortages, operational problems, and the slow progress of clinical trials involving non-COVID-19 therapeutics.

For instance, in May 2022, EVER Pharma announced that Bortezomib has received EU-wide approval for the treatment of individuals with symptomatic myeloma and mantle cell lymphoma1. In May 2022, The European Commission approved Novartis' Jakavi post-steroid therapy for acute and chronic graft-versus-host ailments. Jakavi will be the first JAK1/2 inhibitor widely available for patients in Europe with steroid-refractory graft-versus-host ailment. In September 2021, Nimble Therapeutics and Incyte entered into strategic collaborative research to discover additional new peptide therapies.

Peptide Therapeutics Market Report Highlights:

• By type, the generic segment is the second largest segment in the market. The rise of generic peptide therapeutics is an emerging trend in the pharmaceutical industry
• Outsourcing manufacturing segment is anticipated to grow at the fastest CAGR during the forecast period owing to the requirements of complex procedures and a shift in preference toward outsourcing, which helps in eliminating the cost of production
• Based on synthesis technology, the recombinant DNA technology segment accounted for the largest revenue share of 79.26% in 2024
• The North America Peptide Therapeutics market maintains a leading position in 2024 with share of 60.21% globally in 2024, driven by the rising prevalence of cancer, metabolic disorders, and rare diseases

Table of Contents

Chapter 1. Methodology and Scope

• 1.1. Market Segmentation and Scope
• 1.2. Market Definitions
• 1.3. Research Methodology
  • 1.3.1. Information Procurement
  • 1.3.2. Information or Data Analysis
  • 1.3.3. Market Formulation & Data Visualization
  • 1.3.4. Data Validation & Publishing
• 1.4. Research Scope and Assumptions
  • 1.4.1. List of Data Sources

Chapter 2. Executive Summary

• 2.1. Market Outlook
• 2.2. Segment Outlook
• 2.3. Competitive Insights

Chapter 3. Peptide Therapeutics Market Variables, Trends, & Scope

• 3.1. Parent Market Outlook
• 3.2. Ancillary Market Outlook
• 3.3. Market Dynamics
  • 3.3.1. Market Drivers Analysis
    • 3.3.1.1. Increasing prevalence of cancer
      • 3.3.1.1.1. Cancer incidence data
    • 3.3.1.2. Technological advancements
    • 3.3.1.3. Presence of strong product pipeline
  • 3.3.2. Market Restraints Analysis
    • 3.3.2.1. Increasing complexity of peptides
    • 3.3.2.2. High cost of manufacturing equipment
• 3.4. Peptide Therapeutics Analysis Tools
  • 3.4.1. Porter's Analysis
    • 3.4.1.1. Bargaining power of the suppliers
    • 3.4.1.2. Bargaining power of the buyers
    • 3.4.1.3. Threats of substitution
    • 3.4.1.4. Threats from new entrants
    • 3.4.1.5. Competitive rivalry
  • 3.4.2. PESTEL Analysis
    • 3.4.2.1. Political landscape
    • 3.4.2.2. Economic and Social landscape
    • 3.4.2.3. Technological landscape
    • 3.4.2.4. Environmental landscape
    • 3.4.2.5. Legal landscape
• 3.5. Pipeline Analysis
  • 3.5.1. Phase 1
  • 3.5.2. Phase 2
  • 3.5.3. Phase 3
• 3.6. Phase 3 Pipeline Drug Forecasts
• 3.7. Case Studies Analysis

Chapter 4. Peptide Therapeutics Market: By Application Estimates & Trend Analysis

• 4.1. Peptide Therapeutics Market: Application Segment Dashboard
• 4.2. Peptide Therapeutics Market: By Application Movement Analysis, 2024 & 2030 (USD Million)
• 4.3. Metabolic Disorders
  • 4.3.1. Metabolic Disorders Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Million)
• 4.4. Cancer
  • 4.4.1. Cancer Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Million)
• 4.5. Neurological Disorders
  • 4.5.1. Neurological Disorders Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Million)
• 4.6. Gastrointestinal Disorders
  • 4.6.1. Gastrointestinal Disorders Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Million)
• 4.7. Cardiovascular Disorders
  • 4.7.1. Cardiovascular Disorders Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Million)
• 4.8. Pain
  • 4.8.1. Pain Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Million)
• 4.9. Infectious Disease
  • 4.9.1. Infectious Disease Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Million)
• 4.10. Renal Disorders
  • 4.10.1. Renal Disorders Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Million)
• 4.11. Dermatological Disorders
  • 4.11.1. Dermatological Disorders Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Million)
• 4.12. Respiratory Disorders
  • 4.12.1. Respiratory Disorders Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Million)
• 4.13. Others
  • 4.13.1. Others Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Million)

Chapter 5. Peptide Therapeutics Market: Type Estimates & Trend Analysis

• 5.1. Peptide Therapeutics Market: Type Segment Dashboard
• 5.2. Peptide Therapeutics Market: By Type Movement Analysis, 2024 & 2030 (USD Million)
• 5.3. Innovative
  • 5.3.1. Innovative Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Million)
• 5.4. Generic
  • 5.4.1. Generic Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Million)
  • 5.4.2. Others Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Million)

Chapter 6. Peptide Therapeutics Market: Type of Manufacturer Estimates & Trend Analysis

• 6.1. Peptide Therapeutics Market: Type of Manufacturer Segment Dashboard
• 6.2. Peptide Therapeutics Market: By Type of Manufacturer Movement Analysis, 2024 & 2030 (USD Million)
• 6.3. Inhouse
  • 6.3.1. Inhouse Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Million)
• 6.4. Outsourced
  • 6.4.1. Outsourced Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Million)

Chapter 7. Peptide Therapeutics Market: Synthesis Technology Estimates & Trend Analysis

• 7.1. Peptide Therapeutics Market: Synthesis Technology Segment Dashboard
• 7.2. Peptide Therapeutics Market: Synthesis Technology Movement Analysis, 2024 & 2030 (USD Million)
• 7.3. Recombinant DNA Technology
  • 7.3.1. Recombinant DNA Technology Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Million)
• 7.4. Solid-Phase Peptide Synthesis (SPPS)
  • 7.4.1. Solid-Phase Peptide Synthesis (SPPS) Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Million)
• 7.5. Hybrid
  • 7.5.1. Hybrid Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Million)
• 7.6. Liquid-Phase Peptide Synthesis (LPPS)
  • 7.6.1. Liquid-Phase Peptide Synthesis (LPPS) Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Million)
• 7.7. Others
  • 7.7.1. Others Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Million)

Chapter 8. Peptide Therapeutics Market: Route of Administration Estimates & Trend Analysis

• 8.1. Peptide Therapeutics Market: Route of Administration Segment Dashboard
• 8.2. Peptide Therapeutics Market: Route of Administration Movement Analysis, 2024 & 2030 (USD Million)
• 8.3. Parenteral Route
  • 8.3.1. Parenteral Route Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Million)
• 8.4. Oral Route
  • 8.4.1. Oral Route Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Million)
• 8.5. Mucosal
  • 8.5.1. Mucosal Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Million)
• 8.6. Pulmonary
  • 8.6.1. Pulmonary Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Million)
• 8.7. Others
  • 8.7.1. Others Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Million)

Chapter 9. Peptide Therapeutics Market: Regional Estimates & Trend Analysis

• 9.1. Peptide Therapeutics Market Share, By Region, 2024 & 2030, USD Million
• 9.2. North America
  • 9.2.1. North America Peptide Therapeutics Market Estimates and Forecasts, 2018 - 2030 (USD Million)
  • 9.2.2. U.S.
    • 9.2.2.1. Key Country Dynamics
    • 9.2.2.2. Target Disease Prevalence
    • 9.2.2.3. Regulatory Framework
    • 9.2.2.4. Reimbursement Framework
    • 9.2.2.5. U.S. Peptide Therapeutics Market Estimates and Forecasts, 2018 - 2030 (USD Million)
  • 9.2.3. Canada
    • 9.2.3.1. Key Country Dynamics
    • 9.2.3.2. Target Disease Prevalence
    • 9.2.3.3. Regulatory Framework
    • 9.2.3.4. Reimbursement Framework
    • 9.2.3.5. Canada Peptide Therapeutics Market Estimates and Forecasts, 2018 - 2030 (USD Million)
  • 9.2.4. Mexico
    • 9.2.4.1. Key Country Dynamics
    • 9.2.4.2. Target Disease Prevalence
    • 9.2.4.3. Regulatory Framework
    • 9.2.4.4. Reimbursement Framework
    • 9.2.4.5. Mexico Peptide Therapeutics Market Estimates and Forecasts, 2018 - 2030 (USD Million)
• 9.3. Europe
  • 9.3.1. Europe Peptide Therapeutics Market Estimates and Forecasts, 2018 - 2030 (USD Million)
  • 9.3.2. UK
    • 9.3.2.1. Key Country Dynamics
    • 9.3.2.2. Target Disease Prevalence
    • 9.3.2.3. Regulatory Framework
    • 9.3.2.4. Reimbursement Framework
    • 9.3.2.5. Uk Peptide Therapeutics Market Estimates and Forecasts, 2018 - 2030 (USD Million)
  • 9.3.3. Germany
    • 9.3.3.1. Key Country Dynamics
    • 9.3.3.2. Target Disease Prevalence
    • 9.3.3.3. Regulatory Framework
    • 9.3.3.4. Reimbursement Framework
    • 9.3.3.5. Germany Peptide Therapeutics Market Estimates and Forecasts, 2018 - 2030 (USD Million)
  • 9.3.4. France
    • 9.3.4.1. Key Country Dynamics
    • 9.3.4.2. Target Disease Prevalence
    • 9.3.4.3. Regulatory Framework
    • 9.3.4.4. Reimbursement Framework
    • 9.3.4.5. France Peptide Therapeutics Market Estimates and Forecasts, 2018 - 2030 (USD Million)
  • 9.3.5. Italy
    • 9.3.5.1. Key Country Dynamics
    • 9.3.5.2. Target Disease Prevalence
    • 9.3.5.3. Regulatory Framework
    • 9.3.5.4. Reimbursement Framework
    • 9.3.5.5. Italy Peptide Therapeutics Market Estimates and Forecasts, 2018 - 2030 (USD Million)
  • 9.3.6. Spain
    • 9.3.6.1. Key Country Dynamics
    • 9.3.6.2. Target Disease Prevalence
    • 9.3.6.3. Regulatory Framework
    • 9.3.6.4. Reimbursement Framework
    • 9.3.6.5. Spain Peptide Therapeutics Market Estimates and Forecasts, 2018 - 2030 (USD Million)
  • 9.3.7. Denmark
    • 9.3.7.1. Key Country Dynamics
    • 9.3.7.2. Target Disease Prevalence
    • 9.3.7.3. Regulatory Framework
    • 9.3.7.4. Reimbursement Framework
    • 9.3.7.5. Denmark Peptide Therapeutics Market Estimates and Forecasts, 2018 - 2030 (USD Million)
  • 9.3.8. Sweden
    • 9.3.8.1. Key Country Dynamics
    • 9.3.8.2. Target Disease Prevalence
    • 9.3.8.3. Regulatory Framework
    • 9.3.8.4. Reimbursement Framework
    • 9.3.8.5. Sweden Peptide Therapeutics Market Estimates and Forecasts, 2018 - 2030 (USD Million)
  • 9.3.9. Norway
    • 9.3.9.1. Key Country Dynamics
    • 9.3.9.2. Target Disease Prevalence
    • 9.3.9.3. Regulatory Framework
    • 9.3.9.4. Reimbursement Framework
    • 9.3.9.5. Norway Peptide Therapeutics Market Estimates and Forecasts, 2018 - 2030 (USD Million)
• 9.4. Asia Pacific
  • 9.4.1. Asia Pacific Peptide Therapeutics Market Estimates and Forecasts, 2018 - 2030 (USD Million)
  • 9.4.2. Japan
    • 9.4.2.1. Key Country Dynamics
    • 9.4.2.2. Target Disease Prevalence
    • 9.4.2.3. Regulatory Framework
    • 9.4.2.4. Reimbursement Framework
    • 9.4.2.5. Japan Peptide Therapeutics Market Estimates and Forecasts, 2018 - 2030 (USD Million)
  • 9.4.3. China
    • 9.4.3.1. Key Country Dynamics
    • 9.4.3.2. Target Disease Prevalence
    • 9.4.3.3. Regulatory Framework
    • 9.4.3.4. Reimbursement Framework
    • 9.4.3.5. China Peptide Therapeutics Market Estimates and Forecasts, 2018 - 2030 (USD Million)
  • 9.4.4. India
    • 9.4.4.1. Key Country Dynamics
    • 9.4.4.2. Target Disease Prevalence
    • 9.4.4.3. Regulatory Framework
    • 9.4.4.4. Reimbursement Framework
    • 9.4.4.5. India Peptide Therapeutics Market Estimates and Forecasts, 2018 - 2030 (USD Million)
  • 9.4.5. Australia
    • 9.4.5.1. Key Country Dynamics
    • 9.4.5.2. Target Disease Prevalence
    • 9.4.5.3. Regulatory Framework
    • 9.4.5.4. Reimbursement Framework
    • 9.4.5.5. Australia Peptide Therapeutics Market Estimates and Forecasts, 2018 - 2030 (USD Million)
  • 9.4.6. South Korea
    • 9.4.6.1. Key Country Dynamics
    • 9.4.6.2. Target Disease Prevalence
    • 9.4.6.3. Regulatory Framework
    • 9.4.6.4. Reimbursement Framework
    • 9.4.6.5. South Korea Peptide Therapeutics Market Estimates and Forecasts, 2018 - 2030 (USD Million)
  • 9.4.7. Thailand
    • 9.4.7.1. Key Country Dynamics
    • 9.4.7.2. Target Disease Prevalence
    • 9.4.7.3. Regulatory Framework
    • 9.4.7.4. Reimbursement Framework
    • 9.4.7.5. Thailand Peptide Therapeutics Market Estimates and Forecasts, 2018 - 2030 (USD Million)
• 9.5. Latin America
  • 9.5.1. Latin America Peptide Therapeutics Market Estimates and Forecasts, 2018 - 2030 (USD Million)
  • 9.5.2. Brazil
    • 9.5.2.1. Key Country Dynamics
    • 9.5.2.2. Target Disease Prevalence
    • 9.5.2.3. Regulatory Framework
    • 9.5.2.4. Reimbursement Framework
    • 9.5.2.5. Japan Peptide Therapeutics Market Estimates and Forecasts, 2018 - 2030 (USD Million)
  • 9.5.3. Argentina
    • 9.5.3.1. Key Country Dynamics
    • 9.5.3.2. Target Disease Prevalence
    • 9.5.3.3. Regulatory Framework
    • 9.5.3.4. Reimbursement Framework
    • 9.5.3.5. China Peptide Therapeutics Market Estimates and Forecasts, 2018 - 2030 (USD Million)
• 9.6. Middle East and Africa
  • 9.6.1. Middle East and Africa Peptide Therapeutics Market Estimates and Forecasts, 2017 - 2030 (USD Million)
  • 9.6.2. South Africa
    • 9.6.2.1. Key Country Dynamics
    • 9.6.2.2. Target Disease Prevalence
    • 9.6.2.3. Regulatory Framework
    • 9.6.2.4. Reimbursement Framework
    • 9.6.2.5. South Africa Peptide Therapeutics Market Estimates and Forecasts, 2018 - 2030 (USD Million)
  • 9.6.3. Saudi Arabia
    • 9.6.3.1. Key Country Dynamics
    • 9.6.3.2. Target Disease Prevalence
    • 9.6.3.3. Regulatory Framework
    • 9.6.3.4. Reimbursement Framework
    • 9.6.3.5. Saudi Arabia Peptide Therapeutics Market Estimates and Forecasts, 2018 - 2030 (USD Million)
  • 9.6.4. UAE
    • 9.6.4.1. Key Country Dynamics
    • 9.6.4.2. Target Disease Prevalence
    • 9.6.4.3. Regulatory Framework
    • 9.6.4.4. Reimbursement Framework
    • 9.6.4.5. UAE Peptide Therapeutics Market Estimates and Forecasts, 2018 - 2030 (USD Million)
  • 9.6.5. Kuwait
    • 9.6.5.1. Key Country Dynamics
    • 9.6.5.2. Target Disease Prevalence
    • 9.6.5.3. Regulatory Framework
    • 9.6.5.4. Reimbursement Framework
    • 9.6.5.5. Kuwait Peptide Therapeutics Market Estimates and Forecasts, 2018 - 2030 (USD Million)

Chapter 10. Competitive Landscape

• 10.1. Recent Developments & Impact Analysis by Key Market Participants
• 10.2. Company Categorization
• 10.3. Participant Overview
• 10.4. Financial Performance
• 10.5. Product Bench Marking
• 10.6. Company Market Share Analysis, 2024
• 10.7. Company Profiles
  • 10.7.1. Eli Lilly and Company
    • 10.7.1.1. Participant's Overview
    • 10.7.1.2. Financial Performance
    • 10.7.1.3. Product Benchmarking
    • 10.7.1.4. Recent Developments/ Strategic Initiatives
  • 10.7.2. Pfizer Inc.
    • 10.7.2.1. Participant's Overview
    • 10.7.2.2. Financial Performance
    • 10.7.2.3. Product Benchmarking
    • 10.7.2.4. Recent Developments/ Strategic Initiatives
  • 10.7.3. Amgen Inc.
    • 10.7.3.1. Participant's Overview
    • 10.7.3.2. Financial Performance
    • 10.7.3.3. Product Benchmarking
    • 10.7.3.4. Recent Developments/ Strategic Initiatives
  • 10.7.4. Takeda Pharmaceutical Company Limited
    • 10.7.4.1. Participant's Overview
    • 10.7.4.2. Financial Performance
    • 10.7.4.3. Product Benchmarking
    • 10.7.4.4. Recent Developments/ Strategic Initiatives
  • 10.7.5. AstraZeneca
    • 10.7.5.1. Participant's Overview
    • 10.7.5.2. Financial Performance
    • 10.7.5.3. Product Benchmarking
    • 10.7.5.4. Recent Developments/ Strategic Initiatives
  • 10.7.6. Teva Pharmaceutical Industries Ltd.
    • 10.7.6.1. Participant's Overview
    • 10.7.6.2. Financial Performance
    • 10.7.6.3. Product Benchmarking
    • 10.7.6.4. Recent Developments/ Strategic Initiatives
  • 10.7.7. Sanofi
    • 10.7.7.1. Participant's Overview
    • 10.7.7.2. Financial Performance
    • 10.7.7.3. Product Benchmarking
    • 10.7.7.4. Recent Developments/ Strategic Initiatives
  • 10.7.8. F. Hoffmann-La Roche Ltd
    • 10.7.8.1. Participant's Overview
    • 10.7.8.2. Financial Performance
    • 10.7.8.3. Product Benchmarking
    • 10.7.8.4. Recent Developments/ Strategic Initiatives
  • 10.7.9. Novartis AG
    • 10.7.9.1. Participant's Overview
    • 10.7.9.2. Financial Performance
    • 10.7.9.3. Product Benchmarking
    • 10.7.9.4. Recent Developments/ Strategic Initiatives
  • 10.7.10. Novo Nordisk A/S
    • 10.7.10.1. Participant's Overview
    • 10.7.10.2. Financial Performance
    • 10.7.10.3. Product Benchmarking
    • 10.7.10.4. Recent Developments/ Strategic Initiatives
  • 10.7.11. GSK plc
    • 10.7.11.1. Participant's Over
    • 10.7.11.2. Financial Performance
    • 10.7.11.3. Product Benchmarking
    • 10.7.11.4. Recent Developments/ Strategic Initiatives
  • 10.7.12. Ironwood Pharmaceuticals, Inc.
    • 10.7.12.1. Participant's Overview
    • 10.7.12.2. Financial Performance
    • 10.7.12.3. Product Benchmarking
    • 10.7.12.4. Recent Developments/ Strategic Initiatives
  • 10.7.13. Radius Health, Inc. (Subsidiary of Gurnet Point Capital and Patient Square Capital)
    • 10.7.13.1. Participant's Overview
    • 10.7.13.2. Financial Performance
    • 10.7.13.3. Product Benchmarking
    • 10.7.13.4. Recent Developments/ Strategic Initiatives
  • 10.7.14. Ipsen Pharma
    • 10.7.14.1. Participant's Overview
    • 10.7.14.2. Financial Performance
    • 10.7.14.3. Product Benchmarking
    • 10.7.14.4. Recent Developments/ Strategic Initiatives

Chapter 11. Conclusion/Key Takeaways/KoL Insights